Key terms
About SRTS
Sensus Healthcare, Inc. is a medical device company, which engages in the provision of treatment for both oncological and non-oncological skin conditions. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman, and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SRTS news
Mar 17
2:01am ET
Navigating Uncertainty: How Global Crises Threaten Sensus Healthcare’s Growth and Operations
Mar 13
8:21am ET
Sensus Healthcare launches ‘Fair Deal Agreement’ for SRT-100 Vision
Feb 10
7:35am ET
Sensus Healthcare: Strong Q4 Performance and Promising Future Drive Buy Rating
Feb 09
9:40am ET
Sensus Healthcare price target raised to $7.50 from $4 at Alliance Global Partners
Feb 09
6:20am ET
Analysts Are Bullish on Top Healthcare Stocks: Foghorn Therapeutics (FHTX), Sensus Healthcare (SRTS)
Feb 08
8:11am ET
Sensus Healthcare issued U.S. patent for SRT-100 vision system
Feb 06
8:21am ET
Sensus Healthcare collaborates with CureRays
Feb 05
9:10am ET
Analysts’ Top Healthcare Picks: Sensus Healthcare (SRTS), Inotiv (NOTV)
Feb 01
8:12am ET
Sensus Healthcare announces retirement of director O’Rear
Jan 24
2:35pm ET
Buy Rating Affirmed for Sensus Healthcare Amidst Strong Performance and Growth Prospects
Jan 24
9:10am ET
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and Sensus Healthcare (SRTS)
Jan 24
6:41am ET
Analysts Offer Insights on Healthcare Companies: Sensus Healthcare (SRTS), Outlook Therapeutics (OTLK) and Leap Therapeutics (LPTX)
Jan 23
8:02am ET
Sensus Healthcare sees Q4 revenue over $12M, consensus $7.52M
No recent news articles are available for SRTS
No recent press releases are available for SRTS
SRTS Financials
Key terms
Ad Feedback
SRTS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SRTS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range